IART — Integra LifeSciences Holdings Corporation

Integra LifeSciences Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 Revenue: $435 million, a decrease of 1.7% reported and 2.5% organic decline.
• Full Year 2025 Revenue: $1.635 billion, representing 1.5% growth reported but a 0.7% organic decline.
• Adjusted EPS: Q4 at $0.83, down from $0.97 year-over-year; Full Year at $2.23, down from $2.56 in 2024.
• Gross Margin: Q4 at 61.7%, down 350 basis points year-over-year; Full Year at 61.9%, down 260 basis points.
• Adjusted EBITDA Margin: Q4 at 24%, up 30 basis points; Full Year at 19.4%, down 60 basis points.
• Cash Flow from Operations: Q4 at $11.8 million; Full Year at $50.4 million.
• Net Debt: $1.6 billion with a consolidated total leverage ratio of 4.5x.

2. Strategic Updates and Business Highlights

• Transformation Initiatives: Focus on quality management, supply chain reliability, and operational execution.
• Leadership Changes: Six new leaders added to the executive team to enhance capabilities.
• Product Launches: Successful early relaunch of PriMatrix and Durepair; new MAYFIELD Ghost launched in the U.S.
• China Strategy: Progress made with regulatory submissions for market entry.
• Supply Chain Improvements: Enhanced operational visibility and manufacturing resiliency efforts.

3. Forward Guidance and Outlook

• Q1 2026 Revenue Guidance: Expected between $375 million and $390 million, reflecting organic growth of -3.4% to +0.5%.
• Full Year 2026 Revenue Guidance: Expected between $1.66 billion and $1.7 billion, reflecting organic growth of 0.8% to 3.3%.
• Adjusted EPS Guidance for Q1 2026: Expected between $0.37 and $0.45, with a $0.07 impact from tariffs.
• Full Year 2026 Adjusted EPS Guidance: Expected between $2.30 and $2.40.

4. Bad News, Challenges, or Points of Concern

• Organic Revenue Decline: Continued supply chain issues and quality remediation efforts impacted organic growth.
• Tariff Uncertainty: Recent Supreme Court ruling on tariffs adds complexity; $20 million in tariffs paid in 2025, with ongoing uncertainty about future impacts.
• Tissue Technologies Segment Decline: Q4 revenues down 12.8% due to remediation issues with MediHoney and tough year-over-year comparisons.
• Free Cash Flow: Negative $5.4 million in Q4, attributed to timing of collections and restructuring costs.

5. Notable Q&A Insights

• Free Cash Flow Improvement: Expected to improve significantly in 2026, with operating cash flow projected to exceed $200 million.
• MediHoney Remediation: No revenue accounted for MediHoney in 2026 guidance; remediation efforts ongoing.
• Market Dynamics: Strong underlying demand remains, but growth is hindered by supply issues rather than lack of demand.
• China Growth: Strong performance expected to continue, contributing positively to overall international sales.

This summary encapsulates the key points from Integra LifeSciences' Q4 2025 earnings call, highlighting both the company's achievements and the challenges it faces moving forward.